BMS-986142 (C09-0785-872)

InformationBMS-986142 BMS-986142 is a potent and highly selective reversible small molecule inhibitor of BTK with an IC50 of 0.5 nM. In a panel of 384 kinases, only five kinases were inhibited by BMS-986142 with less than 100-fold selectivity for BTK (TEC, ITK, BLK, TXK and BMX).TargetsBTK (Cell-free assay) 0.5 nMIn vitroIn B cells stimulated through the B cell receptor (BCR), BMS-986142 potently inhibits signaling and functional end points, including calcium flux (IC50 = 9 nM), production of cytokines, proliferation, and surface expression of the costimulatory molecule CD86 (IC50 = 3−4 nM). In T cells, ITK-catalyzed phosphorylation of PLCγ1 stimulated through the T cell receptor (TCR) is at least 45-fold less potently inhibited by BMS-986142 than BTK-dependent signaling end points in B cells, as expected based on the 30-fold selectivity for BTK over ITK in the enzymatic assays.In vivoIn multispecies pharmacokinetic studies, the absolute oral bioavailability of BMS-986142 is 93% in mice, 67% in rats, 33% in cynomolgus monkeys, and 100% in dogs. The total body plasma clearance of BMS-986142 is low in all species. The large steady-state volume of distribution observed is indicative of extravascular distribution, in spite of the high protein binding. However, brain penetration is very low in rats (<5% of plasma concentration). BMS-986142 blocks the increase in severe proteinuria in a female NZB/W lupus-prone mouse model in vivo. Treatment with BMS-986142 provides robust protection against tubulo-interstitial and glomerular nephritis, as well as inflammatory infiltration.Cell Research(from reference)Cell lines：Ramos B cells Concentrations：0.4, 1.6, 6, 25, 100 and 400 nM Incubation Time：1 h. Specification: 0.99 Molecular Formula: C32H30F2N4O4 Molecular Weight: 572.6 PubChem CID: 86582336 Isomeric SMILES: CC1=C(C=CC=C1N2C(=O)C3=C(C(=CC=C3)F)N(C2=O)C)C4=C(C=C(C5=C4C6=C(N5)C[C@H](CC6)C(C)(C)O)C(=O)N)F